BioCardia, a clinical stage regenerative medicine company developing a cell-based therapy to treat heart failure, has filed for an IPO. Planning to list on the NASDAQ under the symbol BCDA, the company expects to price shares in a range between $12 and $14 each, which would raise the company roughly $50 million if shares priced at the midpoint. BioCardia last raised a $16 million financing at a valuation of $75 million in May 2013. Current shareholders include the Stertzer Family Trust (18.2% pre-IPO stake) and Sabiah (12.8%). A portion of the proceeds will go to fund the FDA accepted Phase III pivotal trial of its CardiAMP Cell Therapy System.